Cargando…
An assessment of the strategy and status of COVID-19 vaccination in India
The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089693/ https://www.ncbi.nlm.nih.gov/pubmed/37041424 http://dx.doi.org/10.1007/s12026-023-09373-5 |
_version_ | 1785022814240112640 |
---|---|
author | Gupta, Sneh Lata Goswami, Surbhi Anand, Ananya Naman, Namrata Kumari, Priya Sharma, Priyanka Jaiswal, Rishi K. |
author_facet | Gupta, Sneh Lata Goswami, Surbhi Anand, Ananya Naman, Namrata Kumari, Priya Sharma, Priyanka Jaiswal, Rishi K. |
author_sort | Gupta, Sneh Lata |
collection | PubMed |
description | The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating viral vector, and inactivated vaccine. Along with that 16 more vaccines are undergoing clinical trials to counter COVID-19. The availability of different vaccines gives alternate and broad perspectives to fight against viral immune resistance and, thus, viruses escaping the immune system by mutations. Using the recently published literature on the Indian vaccine and clinical trial sites, we have reviewed the development, clinical evaluation, and registration of vaccines trial used in India against COVID-19. Moreover, we have also summarized the status of all approved vaccines in India, their associated registered clinical trials, manufacturing, efficacy, and their related safety and immunogenicity profile. |
format | Online Article Text |
id | pubmed-10089693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-100896932023-04-12 An assessment of the strategy and status of COVID-19 vaccination in India Gupta, Sneh Lata Goswami, Surbhi Anand, Ananya Naman, Namrata Kumari, Priya Sharma, Priyanka Jaiswal, Rishi K. Immunol Res Review The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating viral vector, and inactivated vaccine. Along with that 16 more vaccines are undergoing clinical trials to counter COVID-19. The availability of different vaccines gives alternate and broad perspectives to fight against viral immune resistance and, thus, viruses escaping the immune system by mutations. Using the recently published literature on the Indian vaccine and clinical trial sites, we have reviewed the development, clinical evaluation, and registration of vaccines trial used in India against COVID-19. Moreover, we have also summarized the status of all approved vaccines in India, their associated registered clinical trials, manufacturing, efficacy, and their related safety and immunogenicity profile. Springer US 2023-04-11 /pmc/articles/PMC10089693/ /pubmed/37041424 http://dx.doi.org/10.1007/s12026-023-09373-5 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Gupta, Sneh Lata Goswami, Surbhi Anand, Ananya Naman, Namrata Kumari, Priya Sharma, Priyanka Jaiswal, Rishi K. An assessment of the strategy and status of COVID-19 vaccination in India |
title | An assessment of the strategy and status of COVID-19 vaccination in India |
title_full | An assessment of the strategy and status of COVID-19 vaccination in India |
title_fullStr | An assessment of the strategy and status of COVID-19 vaccination in India |
title_full_unstemmed | An assessment of the strategy and status of COVID-19 vaccination in India |
title_short | An assessment of the strategy and status of COVID-19 vaccination in India |
title_sort | assessment of the strategy and status of covid-19 vaccination in india |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089693/ https://www.ncbi.nlm.nih.gov/pubmed/37041424 http://dx.doi.org/10.1007/s12026-023-09373-5 |
work_keys_str_mv | AT guptasnehlata anassessmentofthestrategyandstatusofcovid19vaccinationinindia AT goswamisurbhi anassessmentofthestrategyandstatusofcovid19vaccinationinindia AT anandananya anassessmentofthestrategyandstatusofcovid19vaccinationinindia AT namannamrata anassessmentofthestrategyandstatusofcovid19vaccinationinindia AT kumaripriya anassessmentofthestrategyandstatusofcovid19vaccinationinindia AT sharmapriyanka anassessmentofthestrategyandstatusofcovid19vaccinationinindia AT jaiswalrishik anassessmentofthestrategyandstatusofcovid19vaccinationinindia AT guptasnehlata assessmentofthestrategyandstatusofcovid19vaccinationinindia AT goswamisurbhi assessmentofthestrategyandstatusofcovid19vaccinationinindia AT anandananya assessmentofthestrategyandstatusofcovid19vaccinationinindia AT namannamrata assessmentofthestrategyandstatusofcovid19vaccinationinindia AT kumaripriya assessmentofthestrategyandstatusofcovid19vaccinationinindia AT sharmapriyanka assessmentofthestrategyandstatusofcovid19vaccinationinindia AT jaiswalrishik assessmentofthestrategyandstatusofcovid19vaccinationinindia |